We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TZOO:NASDAQTravelzoo Analysis

Data as of 2026-05-06 - not real-time

$9.09

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Travelzoo is trading just above its discounted cash‑flow estimate, suggesting a marginal premium that is offset by a forward price‑to‑earnings multiple well below the industry average. The company delivers high gross margins and a modest revenue growth rate of around five percent, while maintaining positive operating and free cash flow. Its balance sheet shows ample cash relative to debt, and the lack of dividend payments underscores a focus on reinvestment. Fundamentally, the stock appears fairly priced with a slight upside potential if earnings continue to improve.
On the technical side, the short‑term moving average sits above the longer‑term average, the MACD line is above its signal, and the histogram is positive, all pointing to bullish momentum. RSI is in the low sixties, indicating strength without being overbought. Volume is trending upward, supporting the price action, but a beta above one and a 30‑day volatility near ninety percent highlight heightened market risk. Upcoming earnings releases provide a catalyst for near‑term price movement, and the current support level offers a buffer against downside. Overall, the blend of solid fundamentals and bullish technical signals favors a cautiously optimistic stance.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Bullish MACD crossover
  • RSI indicating strong momentum
  • Increasing trading volume

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward PE well below industry average
  • Consistent free cash flow generation
  • Revenue growth and high gross margins

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Elevated beta and volatility
  • Solid cash position versus debt
  • Strategic focus on subscription and deal platforms

Key Metrics & Analysis

Financial Health

Revenue Growth4.90%
Profit Margin4.32%
P/E Ratio23.9
ROA8.17%
P/B Ratio-13.2
Op. Cash Flow$6.2M
Free Cash Flow$5.6M
Industry P/E17.3

Technical Analysis

TrendNeutral
RSI62.5
Support$5.99
Resistance$11.98
MA 20$8.25
MA 50$7.06
MA 200$7.93
MACDBullish
VolumeIncreasing
Fear & Greed Index90.38

Valuation

Fair Value$8.79
Target Price$21.00
Upside/Downside131.02%
GradeFair
TypeBlend

Risk Assessment

Beta1.31
Volatility88.31%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.